Bennett, Stephanie
Verry, Camille
Kaza, Evangelia
Miao, Xin
Dufort, Sandrine
Boux, Fabien
Crémillieux, Yannick
de Beaumont, Olivier
Le Duc, Géraldine
Berbeco, Ross
Sudhyadhom, Atchar
Clinical trials referenced in this document:
Documents that mention this clinical trial
Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging
https://doi.org/10.1038/s41598-024-62389-1
Article History
Received: 22 January 2024
Accepted: 16 May 2024
First Online: 25 May 2024
Competing interests
: Géraldine Le Duc discloses patent No. WO2021/019268A1, which protects the AGuIX nanoparticles described in this publication. Sandrine Dufort and Géraldine Le Duc own shares in NH Theraguix (Meylan, France), which develops the AGuIX nanoparticles. Olivier de Beaumont and Géraldine Le Duc own stock options at NH Theraguix. Sandrine Dufort, Olivier de Beaumont and Géraldine Le Duc are all employees at NH TherAguix, along with Fabien Bouscx. Yannick Crémillieux discloses grants with Agence Nationale de la Recherche Scientifique and Agence Nationale Recherche Technologie; he is also a consultant for NH Theraguix. Xin Miao is an employee of Siemens Medical Solutions USA Inc. The remaining authors declare no competing interests.